15 May 2019
EMA/HMPC/278211/2019 **FINAL**
Inspections, Human Medicines Pharmacovigilance & Committees Division

Committee on Herbal Medicinal Products (HMPC)

Minutes for the meeting on 14-16 January 2019

Chair: Marisa Delbò Vice-Chair: Emiel van Galen

14 January 2019, 14:00 – 19:00, 2F

15 January 2019, 09:00 – 19:00, 2F

16 January 2019, 09:00 – 16:00, 2F

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed.

Of note, the minutes is a working document primarily designed for HMPC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room).

1.2. Adoption of agenda

HMPC agenda for 14-16 January 2019

Time schedule for 14-16 January 2019

Outcome:
Agenda adopted.

Time schedule endorsed.

1.3. Adoption of the minutes

HMPC minutes for 19-20 November 2018

Outcome:
Minutes adopted.

2. EU herbal monographs and list entries for adoption

2.1. Report on MLWP activities

2.1.1. MLWP minutes 25-27 September 2018

Report: MLWP Chair

Action: For adoption

Document: MLWP Minutes 25-27 September 2018

Minutes adopted.

2.1.2. Appointment of Rapporteurs and Peer-reviewers

Report: HMPC Chair

Action: for adoption
Adopted.

Change of Rapporteurs (Revision)

Orthosiphonis folium – New Rapporteur

Rosmarini aetheroleum – New Rapporteur

Rosmarini folium – New Rapporteur

In preparation for the UK withdrawal from the European Union new Rapporteurs and Peer reviewers were identified for transfer.

Rapporteur transfer after March 2019

Agrimoniae herba (revision) – New Rapporteur

Boldi folium (revision) – New Rapporteur

Calendulae herba (new assessment) – New Rapporteur

Frangulae cortex (revision) – New Rapporteur

Rhamni purshianae cortex (revision) – New Rapporteur

Rhei radix (revision) – New Rapporteur

Peer-Reviewer transfer after March 2019

Bursae pastoris herba (revision) – New PR

Colae semen (revision) – New PR

Frangulae cortex (revision) – New PR

Lupuli flos (revision) – New PR

Melissae folium (revision) – New PR

Rosmarini aetheroleum (revision) – New PR

Rosmarini folium (revision) – New PR

Sabalis serrulatae fructus (revision) – New PR

Thymi herba (revision) – New PR

Violae tricoloris herba (revision) – New PR

2.1.3. Overview of status of HMPC and MLWP assessment work including the Rapporteurship distribution – Status in January 2019

Report: HMPC Chair, MLWP Chair
Action: For discussion

Documents: Overview

Outcome:
Updated (see also agenda points 2.1.2 and 5.7.1).
By adoption of the work plan the HMPC confirmed to start the review procedure for several substances in order to decide whether new relevant data are available which requires the revision of existing EU herbal monographs:

Arctii radix (Rapp., PR)

Juniperi aetheroleum (Rapp., PR)

Juniperi pseudo-fructus (Rapp., PR)

Orthosiphonis folium (Rapp., PR)

Rosmarini aetheroleum (Rapp., PR)

Rosmarini folium (Rapp., PR)

Taraxaci folium (Rapp., PR)

Taraxaci radix cum herba (Rapp., PR)

As an initial step of the review/ revision procedure (EMA/HMPC/124695/2011 Rev. 2) calls for new data since publication of the previous monograph will be published on the EMA website.

2.2. Revised EU herbal monographs and list entries for final adoption

None

2.3. Revised EU herbal monographs and list entries for public consultation

None

2.4. Reviewed EU herbal monographs and list entries for decision on revision

2.4.1. Monograph on Bursae pastoris herba and supporting documents

Action: for adoption
Documents: Review report; References: 06/06

Outcome:
HMPC agreed with the Rapporteur's position that no monograph revision is needed, because no new data of relevance were detected that would change the content of the monograph.

The HMPC decided by consensus not to revise the monograph, assessment report and list of references on Bursae pastoris herba.

The review report was adopted and will be published as an addendum to the existing assessment report on the EMA website.

Some new *in vitro* and clinical studies were identified, without direct impact on the monograph. The herbal preparations used in clinical studies were insufficiently characterised. The market overview revealed a new registered preparation. Since this dry

extract corresponds to a liquid extract already included in the monograph, a revision was not considered necessary.

2.4.2. Monograph on Leonuri cardiacae herba and supporting documents

Action: for adoption
Documents: Review report; References: 24/24

Outcome:
HMPC agreed with Rapporteurs position that no monograph revision is needed because no new data of relevance were detected that would change the content of the monograph.

The HMPC decided by majority not to revise the monograph, assessment report and list of references on Leonuri cardiacae herba.

The review report was adopted and will be published as an addendum to the existing assessment report on the EMA website.

New chemical and *in vitro* studies as well as review articles were found without direct impact on the monograph. A clinical study with a preparation not included in the current monograph (soy bean oil extract) was not taken into account.

Several members expressed concerns with regard to indication 2 of the original monograph reflecting previous divergent opinions (appropriateness for self-medication). Partially additional warnings were advocated. However, since no relevant new safety data were identified, a majority agreed to keep the monograph unchanged.

Divergent opinions: L Anderson, A Lê, AP Martins, MH Pinto-Ferreira

The Norwegian delegate expressed a divergent position.

2.4.3. Monograph on Millefolii flos and supporting documents

Action: for adoption
Documents: Review report; References: 10/06

Outcome:
HMPC agreed with the Rapporteurs' position that no monograph revision is needed, because no new data of relevance were detected that would change the content of the monograph.

The HMPC decided by consensus not to revise the monograph, assessment report and list of references on Millefolii flos.

The review report was adopted and will be published as addendum to the existing assessment report on the EMA website.

Three new clinical studies were identified. However, medicinal products corresponding to the preparations used in the studies are not available on the EU market. Only in one study the preparation used complies with preparation a) in the current EU herbal monograph, but the posology is significantly higher compared to monograph and medicinal products on the EU market. Therefore, criteria for the well-established use were not considered fulfilled.

2.4.4. Monograph on Millefolii herba and supporting documents

Action: for adoption
Documents: Review report; References: 10/06

Outcome:

New relevant data were identified. Rapporteur to update the review report. The decision on the revision and adoption of the review report was postponed to the **HMPC May meeting**.

New data on genotoxicity had been made available that would change the content of the current monograph and potentially allow a corresponding list entry for preparations covered by the test (tea, expressed juice) taking into account HMPC guidelines EMEA/HMPC/107079/2007 and EMEA/HMPC/67644/2009.

2.4.5. Monograph on Phaseoli fructus (sine semine) and supporting documents

Action: for adoption
Documents: Review report; References: 09/09

Outcome:
HMPC agreed with Rapporteur's position that no monograph revision is needed because no new data of relevance were detected that would change the content of the monograph.

The HMPC decided by consensus not to revise the monograph, assessment report and list of references on Phaseoli fructus (sine semine).

The review report was adopted and will be published as an addendum to the existing assessment report on the EMA website.

Some new references were considered to be relevant for the assessment but not changing the content of the current monograph. These include results of non-clinical studies describing hypoglycemic, hypolipidemic, antibacterial and antioxidant activity. Many other references contain data that concern only beans (Phaseolus vulgaris semine) but not the pods and were not taken into account.

2.4.6. Monograph on Tormentillae rhizoma and supporting documents

Action: for adoption
Documents: Review report; References: 19/18

Outcome:
HMPC agreed with the Rapporteur's position that no monograph revision is needed, because no new data of relevance were detected that would change the content of the monograph.

The HMPC decided by consensus not to revise the monograph, assessment report and list of references on Tormentillae rhizoma.

The review report was adopted and will be published as an addendum to the existing assessment report on the EMA website.

New relevant references include only results on the chemistry of secondary metabolites of tormentil, together with some non-clinical studies (*in-vitro* and *in-vivo*) related mainly to anti-inflammatory, antioxidant, antithrombotic and vasoconstrictive properties. No new references are related to efficacy or safety.

2.5. EU herbal monographs, list entries and public statements for final adoption

None

2.6. EU herbal monographs, list entries and public statements for adoption for release for public consultation

None

2.7. EU herbal monographs, list entries and public statements - post finalisation

2.7.1. Monograph on Pistacia lentiscus, resina (mastic) and supporting documents

Action: for adoption
Documents: MO, AR, LoR, Presentation; References: 101/78

Outcome:

HMPC agreed to post-adoption changes including substance name, corrections in AR and new references added to LoR. Documents with further changes according to the discussion will be distributed for comments to be received by 28 February 2019 before final agreement at the May 2019 meeting.

3. Referral procedures

None

4. Guidelines and guidance documents

4.1. Non-clinical/clinical safety and efficacy and multidisciplinary

4.1.1. Public statement on the use of herbal medicinal products containing estragole

Action: for discussion
Documents: Draft revised PS; OoC; Comments; SWP subgroup comments; Presentation

Outcome:

HMPC discussed information on implementation of current PS conclusions for specific preparations in HMPC monographs and products as well as a draft decision tree for consideration.

Challenging upcoming case-by-case decisions were shown (actual estragole exposures as per preparation and age group) for specific posologies in relevant monographs/products when following the PS recommendations. Additional clarifications were advocated for in order to improve usability by assessors. The draft decision tree was welcomed, in principle, however, details need to be further elaborated/modified and the usability tested with specific examples.

Members discussed practicalities of non-availability of a specific exposure limit in contrast to other assessments (e.g. pulegone) as well as ranges/factors vis-à-vis associated risks in view of insufficient data available to establish a strict limit value.

4.1.2. Public statement on the contamination of herbal medicinal products/traditional herbal medicinal products with pyrrolizidine alkaloids (EMA/HMPC/328782/2016)

Action: for adoption
Documents: Draft public information

Outcome:
Draft public update to EMA/HMPC/328782/2016 was adopted by consensus for inclusion into the January public meeting report:

Since the HMPC Public Statement from May 2016, new information on the risks of pyrrolizidine alkaloids in honey, tea, herbal infusions (herbs) and food supplements was published by EFSA [EFSA, 2017].

Furthermore, the EDQM has established a Working Party to develop a general method for testing pyrrolizidine alkaloids [EDQM, 2017]; this work is ongoing.

Due to ongoing European discussions and efforts for harmonization to characterise the risk of exposure of PAs to human health, the HMPC has agreed to extend the transitional period for products with levels up to 1.0 µg PAs per day for a further 2 years.

Whilst difficulties for manufacturers of herbal medicinal products to implement measures to reduce PA contamination are acknowledged, manufacturers should continue to take appropriate actions, including implementation of enhanced GACP, to ensure daily intake does not exceed 1.0 µg PAs per day.

As part of the HMPC work plan, the public statements on pyrrolizidine alkaloids (PAs) (EMA/HMPC/328782/2016 and EMA/HMPC/893108/2011) will be revised to provide direction/guidance for industry and NCAs.

References:

EFSA Risks for human health related to the presence of pyrrolizidine alkaloids in honey, tea, herbal infusions and food supplements. EFSA Journal 2017, 15(7): 4908. Available at: https://www.efsa.europa.eu/en/efsajournal/pub/4908. Accessed 12/2018

EDQM. Outcome of the 157th Session of the European Pharmacopeia Commission. 2017. Available at: https://www.edqm.eu/sites/default/files/edqm_press_release_pheur_comm_157th_session_march_2017.pdf. Accessed 12/2018

HMPC agreed to start the revision of the PS with a Call for data (6 months).

4.1.3. Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) (EMA/HMPC/893108/2011)

Action: for discussion
Documents: PS; Expert report; Statement by EFSA CONTAM panel on Risks for human health related to the presence of pyrrolizidine alkaloids in food

Outcome:

See also 4.1.2.

HMPC agreed to start the revision of the PS with a Call for data (6 months).

4.2. Quality

None

4.3. Regulatory / Procedural

None

4.4. Report on HMPC Drafting Groups activities

4.4.1. Quality DG

None

4.4.2. ORGAM DG

None

5. Organisational, regulatory and methodological matters

5.1. Mandate and organisation of the HMPC

5.1.1. Strategic Review and Learning Meetings

- Follow up on Austria Presidency meeting – Vienna, 15-17 Oct 2018
  Report: HMPC Chair, HMPC Vice-Chair
  Action: for discussion
  Documents: Minutes; Presentations on working methodology

  Outcome:

  Postponed. HMPC Chair proposed that the follow-up of the Vienna meeting will be merged with the follow up of the Bucharest 2017 SRLM for the optimization of MLWP/HMPC work following the restart of the MLWP.

- Romania Presidency meeting – April 2019
  Action: for discussion
  Document: Draft agenda

  Outcome:

  Members were invited to the HMPC SRLM under the Romanian EU presidency: 4-5 April 2019 at the National Agency of Medicines and Medical Devices, Bucharest. Practical information and a modified draft agenda will be distributed. Proposals for contributions should be provided to the Romanian HMPC member.

5.1.2. Preparation of election of Co-opted member

Report: HMPC Chair
Action: for discussion
Documents: Expertise of HMPC members; HMPC rules of procedure

Outcome:
The mandate of the current co-opted member on toxicology expires 03 April 2019.
HMPC confirmed the need for a 5th co-opted member and the need for additional expertise in Toxicology.
A call for nomination will be sent out in preparation of the election in May.

5.1.3. Preparation of election of QDG Chair

Report: HMPC Chair
Action: for discussion
Documents: Expertise of HMPC members; QDG mandate

Outcome:
The mandate of the current Chair of the Quality Drafting Group expires 10 March 2019.
A call for nomination will be sent out in preparation of the election in May.
HMPC also noted that due to the UK's withdrawal from the EU, a position as QDG member may become available and a call for expression of interest will be sent out after March 2019 as appropriate.

5.2. Coordination with EMA Scientific Committees or CMDh-v

5.2.1. Scientific Coordination Board Meeting

Report: HMPC Chair
Action: for information
Document: Draft Minutes 22 November 2018

Outcome:
Postponed.

5.2.2. Coordination with PDCO/PRAC

- Discussion paper of age limitation of use of cough and cold herbal medicinal products in children
  Action: for discussion
  Documents: Draft discussion paper, OoC, Draft overview on cough and cold HMPs in EU

  Outcome:

  A draft discussion paper was presented and draft questions agreed for further development. The Rapporteur will distribute a questionnaire to HMPC members for collection of information on national situations.

  The Rapporteur described the background of the document and four specific questions that could be brought forward to the PDCO related to age limit, route of administration, data required for a contraindication and relevance of usage data. The committee discussed the scope with focus on the Hedera situation in different member states and the availability of general and specific data for PhV measures and monograph content. It was encouraged to formulate the HMPC position(s) on each question in order to streamline the coordination.

5.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

5.4. Cooperation within the EU regulatory network

5.4.1. Coordination with the European Commission

None

5.4.2. Coordination with European Pharmacopoeia

None

5.4.3. Understanding the training needs of NCA assessors involved in the work of the HMPC: Priority needs and plans for training 2019 – 2020

Action: for discussion
Document: Presentation

Outcome:

HMPC agreed to the presented next steps.

Members to provide available material for training by 15 March 2019.

Volunteers for the steering committee should inform the secretariat by 15 March 2019.

Small steering group (suggested areas: quality; pre-clinical; toxicology) to be established in May 2019 HMPC. Meetings will then be organised to develop a list of recommended areas for training (July 2019). Proposals to be used as basis for survey of HMPC – with the aim to agree list of priority areas and develop action list for inclusion in future work plan (September 2019).

The scope was confirmed: training from assessors at NCAs for assessors at NCAs.

5.5. Cooperation with International Regulators

None

5.6. Contacts of the HMPC with external parties and interaction with the Interested Parties to the Committee

None

5.7. Work plan

5.7.1. HMPC work plan 2019

Report: HMPC Chair
Action: for adoption
Documents: Draft work plan 2019 including Annex 1 (monographs) and Annex 2 (guidelines)

Outcome:

Adopted with changes for publication.

Actions for 2019 and topic leads/ Rapporteurs were discussed and agreed one by one, taking into account the specific circumstances in 2019 due to BCP, the move and resource limitations.

According to decisions for the work plan including Rapporteur distribution and start of review procedures (starting with publication of Calls for data), relevant tracking documents will be updated and documents published according to standard procedure (see also 2.1.2 and 2.1.3).

5.8. Planning and reporting

None

5.9. Legislation and regulatory affairs

None

6. EU herbal monographs and list entries in preparation

6.1. Revision of EU herbal monographs and list entries in preparation for adoption after public consultation

6.1.1. Monograph on Hyperici herba and supporting documents – postponed

6.1.2. Monograph on Menthae piperitae folium and supporting documents

Action: for discussion
Documents: Draft revised MO, AR, LoR; References: 109/205

Outcome:
Changes were introduced in the MO. Rapporteur to implement changes according to the discussion.

Documents to be transmitted for peer-review prior to possible **final adoption**.

The linked procedure for the draft revised monograph on Menthae aetheroleum (shared AR and LoR, see 6.2.3) was noted allowing final opinion and publication only with finalised documents.

Timetable:
Members to provide final comments on Menthae aetheroleum/folium to Rapporteur: **28 February**

Documents to be sent to peer-reviewer: **31 March 2019**
Peer-review documents to be sent to Rapporteur: **15 April 2019**
Final documents to be included latest in 2nd premail: **7 May 2019**

6.1.3. Monograph on Valerianae radix/Lupuli flos and supporting documents

Action: for discussion
Documents: MO, AR, LoR, OoC, DE comments on AR, Readers guidance; References: 11/35

Outcome:
Changes were introduced in the documents. Rapporteur to implement further changes according to the discussion.

Documents to be transmitted for peer-review prior to possible **final adoption** in May 2019.

Timetable:
Documents to be sent to peer-reviewer: **31 March 2019**
Peer-review documents to be sent to Rapporteur: **15 April 2019**
Final documents to be included latest in 2nd premail: **7 May 2019**

The Rapporteur presented a reader's guide aside standard documents to summarise previous discussions and comments received.

Major discussion points were AR section 2 (in particular content of table 3 vis-à-vis content of table 1 and 2 and the monograph) and AR section 4 (clinical data table 4 and conclusions). Rapporteur, Chair and members discussed standard approaches in presenting available information in text and corresponding tables and specific challenges during the revision when no new information is available but the latest template format applied (e.g. clinical relevance in table 4), which requires a more detailed presentation than during the first assessment. Reference was also made to the best practice guide.

6.2. Revision of EU herbal monographs and list entries in preparation for public consultation

6.2.1. Monograph on Frangulae cortex and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR; References: 42/43

Outcome:
Draft revised monograph and supporting documents were adopted by consensus for 3 months public consultation.

Changes compared to the first version of the monograph and supporting documents were presented by the Rapporteur. While there are no fundamentally new data available for Frangula, the revision followed largely the new data and approach of Senna and Aloe as blueprint for all anthraquinone laxatives monographs.

6.2.2. Monograph on Hippocastani semen and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR, Readers guidance; References: 00/80

Outcome:
Draft revised documents to be transmitted for peer-review prior to possible **adoption for release for public consultation** in May 2019.

Timetable:
Documents to be sent to peer-reviewer: **31 March 2019**
Peer-review documents to be sent to Rapporteur: **15 April 2019**
Final documents to be included latest in 2nd premail: **7 May 2019**

Based on the Readers Guide the Rapporteur presented changes in the monograph (mainly sections 2 and 4.2 linked to the new Ph. Eur. monograph and assay) as well as the AR. It was further proposed to include information from signal detection/ EudraVigilance in the AR as agreed part of a pilot phase (HMPC work plan 2018/2019) to test suitability of available PhV data for HMPC assessment work.

6.2.3. Monograph on Menthae piperitae aetheroleum and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR, LE; References: 109/205

Outcome:

Changes were introduced in the MO and the AR. Draft revised LE to be modified by the Rapporteur using the current template. Rapporteur to implement further changes according to the discussion.

Documents to be transmitted for peer-review prior to possible **adoption for release for public consultation** in May 2019.

Timetable:
Members to provide final comments on Menthae aetheroleum/folium to Rapporteur: **28 February 2019**

Documents to be sent to peer-reviewer: **31 March 2019**
Peer-review documents to be sent to Rapporteur: **15 April 2019**
Final documents to be included latest in 2nd premail: **7 May 2019**

The Rapporteur presented relevant sections of the AR and consequences for the monograph on both folium (after public consultation, see 6.1.2) and aetheroleum. For folium, the children posology should be checked (consistent clear information in AR vs MO). After final comments from members and peer review, clean versions of all documents should be made available for the May meeting.

6.2.4. Monograph on Rhamni purshianae cortex and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR; References: 00/00

Outcome:
Draft revised documents to be transmitted for peer-review prior to possible **adoption for release for public consultation** in May 2019.

Timetable:
Package to be transferred to the new Rapporteur: **15 February 2019**

Documents to be sent to peer-reviewer: **31 March 2019**
Peer-review documents to be sent to Rapporteur: **15 April 2019**
Final documents to be included latest in 2nd premail: **7 May 2019**

While there are no essentially new data available for Rhamnus, the revision followed largely the new data and approach of Senna and Aloe as blueprint for all anthraquinone laxatives monographs.

Some modifications still have to be performed in the AR, references compiled and information on a product authorised in Spain to be confirmed. All documents and literature will be transferred to the new Rapporteur (see timetable).

6.2.5. Monograph on Rhei radix and supporting documents - postponed

6.2.6. Monograph on Tanaceti parthenii herba and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR, Presentation; References: 00/103

Outcome:
Rapporteur to clarify posology, period of use, safety aspect with the new posology.

Documents to be sent to peer-reviewer: **15 March 2019**
Peer-review documents to be sent to Rapporteur: **15 April 2019**
Final documents to be included latest in 2nd premail for (final) discussion and possible adoption for public consultation at the **HMPC May meeting**: **7 May 2019**

Committee members discussed the history of posology of products on the market. Concerns were raised with regard to the 6-fold dosage increase compared to the previous monograph. An even higher posology originating from some food supplements (260 mg 3x times daily) was noted. In view of this substantial increase the relevance of some safety aspects should be double-checked (AR and MO sections 4.3, 4.4 4.6 and 5.3). This includes the use during pregnancy and lactation (warning vs contraindication) considering maximum daily dose and HED since animal studies have shown some signs of reproductive toxicity.

6.2.7. Monograph on Thymi aetheroleum and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR; References: 119/138

Outcome:
Rapporteur to implement changes in the documents according to the discussion for discussion at the **HMPC May meeting**.

The Rapporteur presented changes to monograph and AR. Newly published data on mutagenicity and genotoxicity of thymol will be considered for changes to monograph section 5.3. A change to the existing list entry was not proposed.

The new Ph. Eur. monograph title 'thyme oil (thymol chemotype)' was noted (previously thyme oil). However, relevance for information given in the AR and monograph including titles and references should be carefully considered. Differences may be discussed with the relevant Ph. Eur. group.

6.2.8. Monograph on Trigonellae foenugraeci semen and supporting documents - postponed

6.3. Review of EU herbal monographs and list entries in preparation for decision on revision

6.3.1. Public Statement on Centellae asiaticae herba and supporting documents - postponed

6.3.2. Monograph on Hamamelidis cortex and supporting documents

Action: for discussion
Document: Review report, Presentation; References: 00/02

Outcome:
HMPC noted availability of a new Ph. Eur. monograph on Hamamelidis cortex.

Rapporteur to implement changes in the review report according to the discussion. Draft review report to be transmitted for peer-review by **28 February 2019** prior to decision on the need for revision at the **HMPC May meeting**.

Members questioned whether the new Ph. Eur. monograph should trigger the revision in this case (slight change in substance specification from 4% to 5% of tannins expressed as pyrogallol) without having a major impact on the assessment or monograph.

Furthermore the relevance of toxicological data (e.g. NTP study) should be discussed in the review report.

It was noted that the three Hamamelis substances share the same AR and LoR. If a revision procedure is started the whole package needs to be revised including all three monographs because the current AR/LoR cannot become superseded for one substance but not for the other two.

6.3.3. Monograph on Hamamelidis folium and supporting documents

Action: for discussion
Document: Review report, Presentation; References: 00/00

Outcome:
Rapporteur to implement changes in the review report according to the discussion. Draft review report to be transmitted for peer-review by **28 February 2019** prior to decision on the need for revision at the **HMPC May meeting**.

See 6.3.2

6.3.4. Monograph on Hamamelidis folium et cortex aut ramunculus destillatum and supporting documents

Action: for discussion
Document: Review report, Presentation; References: 00/00

Outcome:
Rapporteur to implement changes in the review report according to the discussion. Draft review report to be transmitted for peer-review by **28 February 2019** prior to decision on the need for revision at the **HMPC May meeting**.

See 6.3.2

6.3.5. Monograph on Quercus cortex and supporting documents

Action: for discussion
Document: Review report; References: 18/10

Outcome:
Postponed

6.3.6. Monograph on Solidaginis virgaureae herba and supporting documents

Action: for discussion
Document: Review report; References: 32/19

Outcome:
Postponed

6.3.7. Public statement on Andrographidis paniculatae folium and supporting documents

Action: for discussion
Document: Review report; References: 25/11

Outcome:
Rapporteur to implement changes in the review report according to the discussion. Draft review report to be transmitted for peer-review prior to decision by the **HMPC in May 2019** whether to start the assessment towards monograph establishment depending on the availability of sufficient data.

HMPC secretariat and HMPC members to provide to the Rapporteur all available information regarding marketed mono and combination products by **31 March 2019**.

Without new MPs registered or authorised in the EU, the Rapporteur considered that there are still insufficient data for a monograph, although the substance seems to be intensely studied with several new non-clinical, clinical and review publications. It was emphasised that the legislation requires information on 15/30 years safe medicinal use, which, like for some other monographs, is not necessarily based on recent EU registrations / authorisations as MP. A closer look at available information for strength, posology and indication of mono and combination products was suggested before closing the opportunity for a monograph.

6.4. EU herbal monographs and list entries in preparation for adoption after public consultation

None

6.5. EU herbal monographs and list entries in preparation for adoption for release for public consultation

6.5.1. Monograph on Calendulae herba and supporting documents - postponed

6.5.2. Monograph on Cisti cretici folium and supporting documents - postponed

6.5.3. Monograph on Herniariae herba and supporting documents – postponed

6.5.4. Monograph on Menyanthes trifoliata folium and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR; References: 55/61

Outcome:
Rapporteur to introduce changes in the documents according to the discussion and prepare specific questions to the HMPC for **a third discussion in May 2019**.

The Rapporteur presented traditional evidence and posology as per indication with some challenges such as for the dosage of the comminuted herbal substances.

HMPC agreed not to include information on Menyanthes rhizoma in the AR because of the deviating plant part with a different composition.

6.5.5. Monograph on Saccharomyces cerevisiae CBS 5926 and supporting documents

Action: for discussion
Documents: Draft MO, Draft LE, Draft AR, Draft LOR; EMA letter to EC, EC response;
References: 02/188

Outcome:
Postponed

6.5.6. Monograph on Salviae miltiorrhizae radix et rhizoma and supporting documents - postponed

6.5.7. Monograph on Species amarae and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR; References: 00/16

Outcome:
Postponed

6.5.8. Monograph on Species digestivae or species stomachicae and supporting documents

Action: for discussion
Documents: Draft MO, AR, LoR; References: 00/18

Outcome:
Rapporteur to finalise documents according to the discussion including introduction of information on *Menyanthes*.

Given the inclusion of several estragole containing substances, the draft monograph should not be published before final amendments with regard to the estragole content according to the decisions taken for the PS on the use of herbal medicinal products containing estragole (see also 4.1.1).

The draft monograph was in principle considered ready for public consultation. Some members questioned the 'flexibility' of combinations vis-à-vis the specific use evidence, but a majority supports the approach already applied for other tea combinations. With the mono-monograph on *Menyanthes* soon to be ready, it was asked to re-consider the substance as possible combination partner. As several substances contain larger or minor amounts of estragole, the final agreement on the estragole PS and the subsequent implementation in the mono-monographs should be awaited before concluding on complex combinations.

6.5.9. Monograph on Species sedativae and supporting documents – postponed

6.5.10. Monograph on Vaccinii macrocarpi fructus and supporting documents – postponed

6.5.11. Monograph on Verbenae citriodorae folium and supporting documents - postponed

7. Any other business

7.1. Topics for discussion

7.1.1. Develop a strategy for use of PhV data/tools in HMPC assessment

Action: for discussion
Documents: Presentations

Outcome:
Postponed.

7.1.2. PSUR single assessment (PSUSA) procedure including nationally authorised products (NAPs) for Pelargonii radix

Action: for discussion
Documents: Presentation

Outcome:
HMPC noted the information from the PRAC procedure.

Currently no new data were identified by the Lead Member State (Rapporteur) to alter the content of the SmPC of the original product. In case of measures taken by PRAC or data emerged during the PSUSA procedure affecting the monograph, the unscheduled review/revision according to procedure EMA/HMPC/124695/2011 Rev. 2 can be initiated. The issue will be re-discussed after finalization of the PSUSA procedure by PRAC.

During the discussion the Rapporteur reminded that the revised version adopted in June 2018 was not a systematic review/revision, but only related to the re-evaluation of clinical studies connected with the BSS score. Meanwhile some new safety-related data are available with possible impact on the monograph content. Therefore the Rapporteur proposed to start the unscheduled review as considered necessary by HMPC (new data available from the PSUSA procedure) or to start the periodic review/revision in 2020. Aim is to update and revise all documents originally adopted in 2012.

7.1.3. 2019 International Forum on Traditional Chinese Medicine (TCM) and Botanical Medicine to be held in Shenzhen from April 25th to 26th, 2019

Report: HMPC Chair, HMPC Vice-Chair
Action: for discussion
Document: Email correspondence from E van Galen

Outcome:
HMPC noted information given by the Vice Chair on conference and his conference participation on behalf of the Dutch Agency.

The Vice Chair informed to use his participation to inform on EMA procedures in order to improve understanding and communication with regard to the possibilities / limits for the HMPC assessment of TCM substances to facilitate national registrations in the EU.

7.2. Documents for information

7.2.1. HMPC

Table of Decisions from HMPC meeting held on 19-20 November 2019

Overview of expertise of members HMPC and subgroups

Meeting report from HMPC meeting held on 19-20 November 2019

Overview of status of HMPC assessment work – priority list

Inventory of herbal substances for assessment work

Abbreviations in HMPC agendas/minutes

Common names of herbal substances in all languages

Overview of status of HMPC/MLWP assessment work

Final Monograph Overview

7.2.2. ARSP

- English template
- English summaries for publication:
  - Wild strawberry leaf
  - Mallow leaf
  - Mallow flower
  - Gentian root
  - Butcher's broom

No objections were raised with regard to the publication of the English summaries on the EMA website.

7.2.3. EU herbal monographs, list entries and public statements – on hold

- Monograph on Allii sativi bulbus and supporting documents
  Action: for information
  Documents: MO, AR, LoR, OoC, email correspondence
- Foeniculi amari fructus and supporting documents – on hold due to Estragole PS
- Foeniculi amari fructus aetheroleum and supporting documents – on hold due to Estragole PS
- Foeniculi dulcis fructus and supporting documents – on hold due to Estragole PS

7.2.4. Other

- PCWP/HCPWP meetings:
  - PCWP - Meeting Summary PCWP Plenary Meeting 25 Sep 2018
  - PCWP/HCPWP - Meeting Summary PCWP/HCPWP Joint Meeting 25 Sep 2018
  - HCPWP - Meeting Summary for the HCPWP Plenary Meeting 26 Sep 2018
- Adapted HMPC Agenda template

- REFIT Platform Opinion on the submission by businesses on the Traditional Herbal Medicinal Products Directive

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 14-16 January 2019 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Marisa Delbò	Chair	Italy	No interests declared	
Astrid Obmann	Alternate	Austria	No interests declared	
Iliana Ionkova	Member	Bulgaria	No interests declared	
Ivan Kosalec	Member	Croatia	No restrictions applicable to this meeting	
Darko Trumbetic	Alternate	Croatia	No interests declared	
Maria Stavrou	Member	Cyprus	No interests declared	
Marie Heroutova	Member	Czech Republic	No interests declared	
Markéta Příhodová	Alternate – via TC	Czech Republic	No interests declared	
Steffen Bager	Member	Denmark	No restrictions applicable to this meeting	
An Le	Member	France	No interests declared	
Susanne Flemisch	Expert	Germany	No interests declared	
Ioanna Chinou	Member	Greece	No interests declared	
Zoi(Zoe) Karampourmpouni	Alternate	Greece	No interests declared	
Zsuzsanna Biróné Dr Sándor	Member	Hungary	No interests declared	
Una Mockler	Alternate – via TC	Ireland	No restrictions applicable to this meeting	
Alessandro Assisi	Member	Italy	No interests declared	
Baiba Jansone	Alternate	Latvia	No interests declared	
Audronis Lukosius	Alternate	Lithuania	No interests declared	
Marcel Bruch	Member	Luxembourg	No interests declared	
Emiel Van Galen	Member	Netherlands	No interests declared	
Burt H Kroes	Alternate	Netherlands	No interests declared	
Steinar Madsen	Member	Norway	No interests declared	
Gro Fossum	Alternate – via TC	Norway	No interests declared	
Wojciech Dymowski	Member	Poland	No interests declared	
Ana Paula Martins	Member	Portugal	No interests declared	
Raluca Iavorszky	Member – via TC	Romania	No interests declared	
Miroslava Petrikova	Member	Slovakia	No interests declared	
Barbara Razinger	Alternate	Slovenia	No interests declared	
Adela Núñez Velázquez	Member	Spain	No interests declared	
Olga Palomino	Expert	Spain	No interests declared	
Karin Erika Svedlund	Member	Sweden	No interests declared	
Malin Kyllikki Hobro Soderberg	Alternate	Sweden	No interests declared	

Linda Anderson	Member	United Kingdom	No interests declared	
Elizabeth Griffiths	Alternate	United Kingdom	No interests declared	
Ewa Balkowiec Iskra	Co-opted member – via TC	Poland	No interests declared	
Silvia Girotto	Co-opted member	Italy	No interests declared	
Gert Laekeman	Co-opted member	Belgium	No interests declared	
Heidi Foth	Co-opted member	Germany	No interests declared	
Maria Helena Pinto Ferreira	Co-opted member	Portugal	No interests declared	